TriPRIL CAR T Cells in Multiple Myeloma
NCT05020444
Recruiting
This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. * TriPRIL CAR T Cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Register for Updates
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
NCT05895201
Withdrawn
This is an open label Phase I-II study to determine the safe doses of bortezomib, sitagliptin, and PTCy (Phase I) with expansion into a phase II trial to determine efficacy in improving survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Bone Marrow Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Register for Updates
CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer
NCT03089203
Active Not Recruiting
This is a single center, single arm Phase I study to establish the safety and feasibility of intravenously administered lentivirally transduced dual PSMA-specific/ TGFβ-resistant CAR modified autologous T cells (CART-PSMA-TGFβRDN cells) in patients with metastatic castrate resistant prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Prostate Cancer
Register for Updates
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
NCT03873805
Active Not Recruiting
This phase I trial studies side effects and best dose of PSCA-chimeric antigen receptor (CAR) T cells in treating patients with prostate stem cell antigen positive (PSCA+) castration resistant prostate cancer that has spread to other places in the body (metastatic). PSCA-CAR T cells are immune cells that have been engineered in the laboratory to kill tumor cells. This is done by using a virus to insert a piece of deoxyribonucleic acid (DNA) into the immune cells that allows them to recognize pro... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
NCT03860844
Terminated
Primary Objective: Evaluate the anti-leukemic activity of isatuximab in combination with standard chemotherapies in pediatric participants of ages 28 days to less than 18 years with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML) Secondary Objectives: * Safety and tolerability assessments * Assessment of infusion reactions (IRs) * Pharmacokinetics (PK) of isatuximab * Minimal residual disease * Overall response rate * Overall survival * Event free surviv... Read More
Gender:
ALL
Ages:
Between 28 days and 17 years
Trial Updated:
04/22/2024
Locations: Sarah Cannon Research Institute-Site Number:8400001, Nashville, Tennessee +40 locations
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Register for Updates
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
NCT03219450
Recruiting
This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: * Personalized NeoAntigen Vaccine * Poly-ICLC * Cyclophosphamide * Pembrolizumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Lymphocytic Leukemia
Register for Updates
Liver Transplantation With Tregs at UCSF
NCT03654040
Terminated
This is a single-center, prospective, open-label, non-randomized clinical trial exploring cellular therapy to facilitate immunosuppression withdrawal in liver transplant recipients.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/22/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Liver Transplant
Register for Updates
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
NCT01659658
Terminated
The purpose of this study is to provide continued access of ixazomib and/or other study medications and to continue collecting relevant safety data to monitor participant's safety, determine whether dexamethasone plus IXAZOMIB improves hematologic response, 2-year vital organ (that is, heart or kidney) deterioration and mortality rate versus a physician's choice of a chemotherapy regimen in participants diagnosed with relapsed or refractory systemic light chain (AL) amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Cedars Sinai Medical Center, Los Angeles, California +65 locations
Conditions: Relapsed or Refractory Systemic Light Chain Amyloidosis
Register for Updates
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
NCT00379340
Active Not Recruiting
This phase III trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with newly diagnosed stage III or stage IV Wilms' tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving more than one drug (combination chemotherapy) with or without radiation therapy may kill mo... Read More
Gender:
ALL
Ages:
29 years and below
Trial Updated:
04/12/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +226 locations
Conditions: Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Register for Updates
Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
NCT01783535
Active Not Recruiting
The primary objective of this protocol is to evaluate the response rate of bilateral disease participants who have at least one eye with advanced intra-ocular retinoblastoma (stratum B) using upfront therapy with chemotherapy delivered directly to the eye. The main biology objective is to improve our understanding of the biology and tumorigenesis (how tumor develops) of retinoblastoma when biology specimens are available. As clinicians, the primary goal of the investigators for children with ret... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/11/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Retinoblastoma
Register for Updates
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
NCT00070564
Active Not Recruiting
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating resected breast cancer. PURPOSE: This randomized phase III trial is comparing 2 different regimens of combination chemotherapy to see how w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Regional Medical Center, Anniston, Alabama +541 locations
Conditions: Breast Cancer
Register for Updates
Mature B-Cell Lymphoma And Leukemia Study III
NCT01046825
Active Not Recruiting
This is a phase III clinical trial using risk-adapted therapy. Treatment outcomes for children with B-cell NHL are excellent. Further improvements in outcome will likely be achieved through more focused study of the biology of the tumors and prospective studies of the late effects of treatment. Toward this end, this study features a spectrum of prospective biologic and late effect studies performed in patients treated with a modified regimen derived from the very successful LMB-96 regimen.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
04/10/2024
Locations: Rady Children's Hospital San Diego, San Diego, California +3 locations
Conditions: Mature B-Cell Lymphoma
Register for Updates